# Alcon share price today (Alcon Inc., ALC)

> Alcon Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. ALC · Healthcare · Medical Instruments & Supplies · data as of 3 November 2026. Page: https://www.sectoralpha.in/us/stocks/alc

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Business trend: Getting worse, from the last 12 quarters
- Price: $72.37 (−2.1% in a year)
- P/E: 55.9×, over 4.6 years
- Revenue (Jun 2026): $2.8 B (+8.7% on a year ago)
- Operating margin: 14.6% (+3.4 points on a year ago)
- ROE: 4%, FY25
- ROIC: 4.7%, against a 7.6% cost of capital: −2.9 points
- Profit that came in as cash: 193%, last 3 years

Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. ## What is the Alcon share price today? Alcon Inc.'s share price was $72.37 at the close on 3 November 2026. It has been stalling near its high for 1 week. That is 0.7% above its average price over the last 200 trading days. Over the past 13 weeks it has done better than the S&P 500, and it has stayed ahead for 3 weeks in a row. In the last 52 weeks it traded between $63 and $87, and at that close it sat 40% of the way up from that low. Over the last 7.6 years the share price moved +33% while the S&P 500 moved +160%, so it is behind the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Alcon pay? Alcon Inc. has 3 quarters of declared dividends on file, too few for a 12-month total. The most recent declaration was $0.35 for Dec 2025. Alcon Inc. declared a dividend in 3 of the last 12 reported quarters, most recently $0.35 for Dec 2025. That is fewer than four quarters, so no 12-month total is shown. ## Which stock lists is Alcon on? Alcon is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is Alcon profitable? Alcon Inc.'s latest quarterly profit is not on file. Full-year FY25 profit was $980 M. Over 4 years profit has grown 27.1% a year on average. Jun 2026 profit was null. For the full year, FY25 profit was $980 M (−3.7% on the year before). On average over the last four quarters, profit changed −26.5% and revenue +8.3%. Profit is growing slower than sales: rising costs are taking part of the growth. ## How much revenue does Alcon make, and is it growing? Alcon Inc. reported $2.8 B of revenue in the Jun 2026 quarter, +8.7% on the same quarter a year earlier. That is the 12th quarter in a row with growth on the year before. Over 4 years it has grown 5.8% a year on average. The last full year, FY25, came in at $10.4 B. The last four reported quarters add to $10.9 B. FY25 revenue was $10.4 B, +4.9% on the year before. Recent pace: the last four quarters grew +8.3% on average, against 5.8% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +8.3%, against +6.2% a year over the last 8 quarters (stabilising). ## How much of every $100 of sales does Alcon keep? Alcon Inc.'s operating margin was 14.6% in the Jun 2026 quarter, 3.4 percentage points higher than the same quarter a year ago. Across 5 years it has been between 9.9% and 13.8%. The latest quarter is above every full year in that period. Why the margin moved: operating margin changed +3.4 percentage points on the year while gross margin changed +4.2 points. So the gain came mostly from the gross margin, which means input costs and prices charged. ## Is Alcon's profit turning into cash? Over the last 3 years, 193% of Alcon Inc.'s reported profit came in as cash from its operations, so the profit is backed by cash. In FY25 it brought in $2.3 B of operating cash against $980 M of profit. After $543 M of spending on assets, $1.7 B was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why: the cash figure is clear, but the day counts behind it are not in our data, so we show it without guessing the reason. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does Alcon's cash go? Alcon Inc. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $1.7 B on assets over the last 3 years. Averaged over those years that is 5.4% of FY25 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $1.7 B over the last 3 years. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Alcon's P/E ratio, and how does it compare with its own history? Alcon Inc.'s P/E is 55.9×, with too little history to compare. This compares the share price with the company’s own past. It does not say what the business is worth. Why the multiple is where it is: over the past year earnings per share moved −3.4% while the price moved −2.1%. The price did better than earnings, which pushed the multiple up within its own range. Where the price move came from: over 3 years the price moved −0.9% a year; about +22.5% a year came from earnings growth and about −23.4 percentage points from the multiple (the market paying less). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: there is too little history to say whether the multiple is high or low for this company, so the earnings trend underneath matters more than the multiple. ## Is the Alcon business getting better or worse? Alcon Inc.'s business is getting worse. Profit and EPS growth are shrinking: profit growth is −26.9% in the latest quarter, against +207.3% at its best in 12 quarters, with ROCE steady at 4.9%. This is based on 12 quarters of 4 measures. Why it matters: falling lines mean any ratio below that looks low should be read with that direction in mind. ## How much does Alcon earn on its capital? Alcon Inc. earned a ROE of 4% in FY25. That is up from a low of 2% in FY22. Its return on capital used (ROIC) is 2.9 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses. It comes from a 9.4% net margin and 0.33× asset turnover (sales divided by assets). Why the return is what it is (FY25): a 9.4% net margin × 0.33× asset turnover × 1.43× leverage (assets divided by equity) ≈ 4.4% on equity. The margin does its share; borrowing plays a small part, so this return is earned, not borrowed. The key test, return on capital used minus the cost of capital: 4.7% − 7.6% = −2.9 percentage points. The 7.6% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve. ## Does Alcon have too much debt? Alcon Inc. has total debt of $5.3 B against shareholder equity of $21.6 B as of Jun 2026, so its debt is 0.25× its equity, which is very little. Year by year, that ratio went from 0.23 in FY21 to 0.24 in FY25. So the returns on this page come from the business, not from borrowed money. ## What is the Alcon shareholding pattern? We have no ownership or short-position figures for Alcon Inc., so this section says so rather than fill the gap. At normal trading volumes, closing those positions would take about 10.6 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. ## How far is Alcon from balance-sheet trouble? For Alcon Inc., the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does Alcon rank in its industry? 47.0 out of 100, rank 16 of 30 in Medical Instruments & Supplies, with 61% of the evidence available. Alcon Inc. scores 47.0 out of 100 against the 30 companies it is compared with in Medical Instruments & Supplies, ranking 16. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. The four parts add up to the total exactly: 18.9 + 11.9 + 9.7 + 6.5 = 47. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Alcon compared with? Alcon ranks 16 of 30 Medical Instruments & Supplies companies on the 4-Factor Sector Score, with 47.0 out of 100. 1. [West Pharmaceutical Services, Inc.](https://www.sectoralpha.in/us/stocks/wst) WST · breaking out · Most evidence points up · 81% evidence 68.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.5/35 · Revenue 12.4% · Profit 15.8% · Operating margin change 1.6 points · 83% evidence Capital efficiency 20.6/25 · ROCE 21.2% · Operating margin 22.5% · 76% evidence Valuation 7.0/20 · P/E 44.9× · PEG 2.65 · 65% evidence Relative strength 17.7/20 · Lead over its industry 15.3% · Lead over S&P 500 26.8% · 1 year 50.2% · 100% evidence · 5 of 12 weeks ahead Exact sum: 23.5 + 20.6 + 7 + 17.7 = 68.8 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 2. [LeMaitre Vascular, Inc.](https://www.sectoralpha.in/us/stocks/lmat) LMAT · turning · Evidence leans up · 81% evidence 62.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 26.7/35 · Revenue 11.5% · Profit 40.4% · Operating margin change 3.9 points · 83% evidence Capital efficiency 17.3/25 · ROCE 11.9% · Operating margin 29% · 76% evidence Valuation 14.0/20 · P/E 33.4× · PEG 0.86 · 65% evidence Relative strength 4.1/20 · Lead over its industry -25.2% · Lead over S&P 500 -17.1% · 1 year -7.2% · 100% evidence · 0 of 12 weeks ahead Exact sum: 26.7 + 17.3 + 14 + 4.1 = 62.1 · What this means: Earnings are strong; relative strength in its sector is -25.2% and the one-year return is -7.2%. 3. [Intuitive Surgical, Inc.](https://www.sectoralpha.in/us/stocks/isrg) ISRG · breaking out · Evidence leans up · 85% evidence 60.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 26.8/35 · Revenue 20.4% · Profit 7.7% · Operating margin change 3 points · 95% evidence Capital efficiency 21.4/25 · ROCE 22% · Operating margin 33.3% · 76% evidence Valuation 4.5/20 · P/E 48.6× · PEG 5.33 · 65% evidence Relative strength 8.0/20 · Lead over its industry -17.1% · Lead over S&P 500 -8.6% · 1 year -21.3% · 100% evidence · 4 of 12 weeks ahead Exact sum: 26.8 + 21.4 + 4.5 + 8 = 60.7 · What this means: A strong business with a high valuation: it would need rising earnings, or a lower multiple, to score better on value. 4. [AtriCure, Inc.](https://www.sectoralpha.in/us/stocks/atrc) ATRC · leader · Evidence leans up · 64% evidence 58.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.2/35 · Revenue 14% · Profit n/a · Operating margin change 10.8 points · 62% evidence Capital efficiency 6.1/25 · ROCE 2.2% · Operating margin 6.3% · 76% evidence Valuation 8.9/20 · P/E 134.3× · PEG n/a · 15% evidence Relative strength 19.6/20 · Lead over its industry 37.3% · Lead over S&P 500 49.6% · 1 year 88.5% · 100% evidence · 12 of 12 weeks ahead Exact sum: 24.2 + 6.1 + 8.9 + 19.6 = 58.8 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 5. [ResMed Inc.](https://www.sectoralpha.in/us/stocks/rmd) RMD · breaking out · Evidence leans up · 81% evidence 57.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 17.8/35 · Revenue 9.8% · Profit 8.8% · Operating margin change -3 points · 83% evidence Capital efficiency 21.5/25 · ROCE 25.4% · Operating margin 30.9% · 76% evidence Valuation 10.2/20 · P/E 18.5× · PEG 1.91 · 65% evidence Relative strength 8.0/20 · Lead over its industry -14.3% · Lead over S&P 500 -5.8% · 1 year -9.7% · 100% evidence · 11 of 12 weeks ahead Exact sum: 17.8 + 21.5 + 10.2 + 8 = 57.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [Bausch + Lomb Corporation](https://www.sectoralpha.in/us/stocks/blco) BLCO · turning · Evidence leans up · 64% evidence 56.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.4/35 · Revenue 8.8% · Profit n/a · Operating margin change 6.8 points · 62% evidence Capital efficiency 7.2/25 · ROCE 3.4% · Operating margin 7.7% · 76% evidence Valuation 11.5/20 · P/E -18.5× · PEG n/a · 15% evidence Relative strength 16.3/20 · Lead over its industry 3.6% · Lead over S&P 500 14% · 1 year 28.8% · 100% evidence · 8 of 12 weeks ahead Exact sum: 21.4 + 7.2 + 11.5 + 16.3 = 56.4 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. [Merit Medical Systems, Inc.](https://www.sectoralpha.in/us/stocks/mmsi) MMSI · quiet · Evidence leans up · 81% evidence 55.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 22.0/35 · Revenue 10.3% · Profit 22.7% · Operating margin change 2.2 points · 83% evidence Capital efficiency 14.3/25 · ROCE 8.1% · Operating margin 14.5% · 76% evidence Valuation 12.7/20 · P/E 28.4× · PEG 1.22 · 65% evidence Relative strength 6.6/20 · Lead over its industry -7% · Lead over S&P 500 1.8% · 1 year -3.9% · 100% evidence · 10 of 12 weeks ahead Exact sum: 22 + 14.3 + 12.7 + 6.6 = 55.6 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 8. [Kestra Medical Technologies, Ltd.](https://www.sectoralpha.in/us/stocks/kmts) KMTS · breaking out · Evidence leans up · 64% evidence 54.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 25.1/35 · Revenue 63.6% · Profit n/a · Operating margin change 27.5 points · 71% evidence Capital efficiency 3.4/25 · ROCE -48% · Operating margin -121.6% · 76% evidence Valuation 10.0/20 · P/E n/a · PEG n/a · 0% evidence Relative strength 15.6/20 · Lead over its industry 4.2% · Lead over S&P 500 14.3% · 1 year 10.6% · 100% evidence · 9 of 12 weeks ahead Exact sum: 25.1 + 3.4 + 10 + 15.6 = 54.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 9. [Becton, Dickinson and Company](https://www.sectoralpha.in/us/stocks/bdx) BDX · breaking out · Evidence leans up · 71% evidence 51.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 14.2/35 · Revenue 5.8% · Profit -40.6% · Operating margin change -1.4 points · 83% evidence Capital efficiency 13.6/25 · ROCE 7.6% · Operating margin 15.7% · 76% evidence Valuation 9.6/20 · P/E 44.3× · PEG n/a · 15% evidence Relative strength 13.6/20 · Lead over its industry -2% · Lead over S&P 500 7.5% · 1 year 11.4% · 100% evidence · 12 of 12 weeks ahead Exact sum: 14.2 + 13.6 + 9.6 + 13.6 = 51 · What this means: Relative strength against the index is 7.5%, and revenue and profit growth are weak. 10. [Repligen Corporation](https://www.sectoralpha.in/us/stocks/rgen) RGEN · leader · Evidence leans up · 74% evidence 50.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 22.6/35 · Revenue 16.5% · Profit n/a · Operating margin change 4.8 points · 62% evidence Capital efficiency 8.9/25 · ROCE 2.3% · Operating margin 9.3% · 76% evidence Valuation 3.7/20 · P/E 185.3× · PEG 8.54 · 65% evidence Relative strength 15.3/20 · Lead over its industry 5% · Lead over S&P 500 15% · 1 year 24.8% · 100% evidence · 12 of 12 weeks ahead Exact sum: 22.6 + 8.9 + 3.7 + 15.3 = 50.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 11. [Baxter International Inc.](https://www.sectoralpha.in/us/stocks/bax) BAX · quiet · Evidence leans up · 64% evidence 50.1 out of 100 Growth Capital Valuation Relative
12. [The Cooper Companies, Inc.](https://www.sectoralpha.in/us/stocks/coo) COO · basing · Evidence leans down · 85% evidence 49.5 out of 100 Growth Capital Valuation Relative
13. [STAAR Surgical Company](https://www.sectoralpha.in/us/stocks/staa) STAA · turning · Too little evidence to rank firmly · 58% evidence 49.2 out of 100 Growth Capital Valuation Relative
14. [Avantor, Inc.](https://www.sectoralpha.in/us/stocks/avtr) AVTR · leader · Evidence leans down · 71% evidence 48.7 out of 100 Growth Capital Valuation Relative
15. [Solventum Corporation](https://www.sectoralpha.in/us/stocks/solv) SOLV · losing its lead · Evidence leans down · 71% evidence 48.3 out of 100 Growth Capital Valuation Relative
16. Alcon Inc. this page ALC · turning · Evidence leans down · 61% evidence 47.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 18.9/35 · Revenue 8.3% · Profit n/a · Operating margin change 3.4 points · 53% evidence Capital efficiency 11.9/25 · ROCE 5% · Operating margin 14.6% · 76% evidence Valuation 9.7/20 · P/E 44× · PEG n/a · 15% evidence Relative strength 6.5/20 · Lead over its industry -14.8% · Lead over S&P 500 -6.2% · 1 year -2.2% · 100% evidence · 2 of 12 weeks ahead Exact sum: 18.9 + 11.9 + 9.7 + 6.5 = 47 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 17. [Azenta, Inc.](https://www.sectoralpha.in/us/stocks/azta) AZTA · leader · Evidence leans down · 64% evidence 46.6 out of 100 Growth Capital Valuation Relative
18. [AptarGroup, Inc.](https://www.sectoralpha.in/us/stocks/atr) ATR · turning · Evidence leans down · 81% evidence 45.6 out of 100 Growth Capital Valuation Relative
19. [Align Technology, Inc.](https://www.sectoralpha.in/us/stocks/algn) ALGN · quiet · Evidence leans down · 81% evidence 44.1 out of 100 Growth Capital Valuation Relative
20. [Stevanato Group S.p.A.](https://www.sectoralpha.in/us/stocks/stvn) STVN · quiet · Evidence leans down · 81% evidence 43.7 out of 100 Growth Capital Valuation Relative
21. [Envista Holdings Corporation](https://www.sectoralpha.in/us/stocks/nvst) NVST · quiet · Too little evidence to rank firmly · 58% evidence 43.2 out of 100 Growth Capital Valuation Relative
22. [Teleflex Incorporated](https://www.sectoralpha.in/us/stocks/tfx) TFX · turning · Evidence leans down · 71% evidence 42.0 out of 100 Growth Capital Valuation Relative
23. [ICU Medical, Inc.](https://www.sectoralpha.in/us/stocks/icui) ICUI · quiet · Evidence leans down · 64% evidence 37.6 out of 100 Growth Capital Valuation Relative
24. [Medline Inc.](https://www.sectoralpha.in/us/stocks/mdln) MDLN · quiet · Too little evidence to rank firmly · 51% evidence 37.3 out of 100 Growth Capital Valuation Relative
25. [DENTSPLY SIRONA Inc.](https://www.sectoralpha.in/us/stocks/xray) XRAY · basing · Most evidence points down · 64% evidence 31.0 out of 100 Growth Capital Valuation Relative
26. [Warby Parker Inc.](https://www.sectoralpha.in/us/stocks/wrby) WRBY · quiet · Most evidence points down · 64% evidence 30.1 out of 100 Growth Capital Valuation Relative
27. [BioLife Solutions, Inc.](https://www.sectoralpha.in/us/stocks/blfs) BLFS · Too little evidence to rank firmly · 44% evidence 48.0 out of 100 Growth Capital Valuation Relative
28. [Pulse Biosciences, Inc.](https://www.sectoralpha.in/us/stocks/plse) PLSE · leader · Too little evidence to rank firmly · 41% evidence 44.0 out of 100 Growth Capital Valuation Relative
29. [MiniMed Group, Inc.](https://www.sectoralpha.in/us/stocks/mmed) MMED · quiet · Too little evidence to rank firmly · 41% evidence 39.1 out of 100 Growth Capital Valuation Relative
30. [Alamar Biosciences, Inc.](https://www.sectoralpha.in/us/stocks/almr) ALMR · turning · Too little evidence to rank firmly · 28% evidence 38.8 out of 100 Growth Capital Valuation Relative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led S&P 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Medical Instruments & Supplies](https://www.sectoralpha.in/us/sectors/medical-instruments-supplies), all 30 compared on one page. ## Which companies are close to Alcon in size? Alcon is the 4th largest of 38 Medical Instruments & Supplies companies on Sector Alpha by market value (scores of 3 November 2026). Just above it: Intuitive Surgical, Inc., Becton, Dickinson and Company and Medline Inc. Just below it: ResMed Inc., West Pharmaceutical Services, Inc. and Solventum Corporation. ### Medical Instruments & Supplies companies close in size

1. [Intuitive Surgical, Inc.](https://www.sectoralpha.in/us/stocks/isrg) $152.8 billion
2. [Becton, Dickinson and Company](https://www.sectoralpha.in/us/stocks/bdx) $54 billion
3. [Medline Inc.](https://www.sectoralpha.in/us/stocks/mdln) $44.8 billion
4. Alcon Inc. $35.2 billion
5. [ResMed Inc.](https://www.sectoralpha.in/us/stocks/rmd) $31.9 billion
6. [West Pharmaceutical Services, Inc.](https://www.sectoralpha.in/us/stocks/wst) $28.4 billion
7. [Solventum Corporation](https://www.sectoralpha.in/us/stocks/solv) $14.4 billion

[All 38 Medical Instruments & Supplies companies, largest first](https://www.sectoralpha.in/us/sectors/medical-instruments-supplies#all-companies)

### Companies close in size in other industries

1. [Steel Dynamics, Inc.](https://www.sectoralpha.in/us/stocks/stld) $35.8 billion · Steel
2. [Elbit Systems Ltd.](https://www.sectoralpha.in/us/stocks/eslt) $35.7 billion · Aerospace & Defense
3. Alcon Inc. $35.6 billion
4. [Vodafone Group Public Limited Company](https://www.sectoralpha.in/us/stocks/vod) $35.6 billion · Telecom Services
5. [Arch Capital Group Ltd.](https://www.sectoralpha.in/us/stocks/acgl) $35.5 billion · Insurance - Diversified

## What else do people ask about Alcon? ### What is Alcon's market cap? Alcon Inc.'s market capitalisation is $35.2 B at a stock price of $72.37. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Alcon performing? Alcon Inc.'s share price has been stalling near its high for 1 weeks. Over the past 13 weeks it has done better than the S&P 500, for 3 weeks running. This describes what the data did, not a rating (as of 3 November 2026). ### Will Alcon's stock price go up? This page does not forecast Alcon Inc.'s stock price. What it shows instead: the stock price is $72.37, and it has been stalling near its high for 1 weeks. Nobody can reliably say which way a price will move, and this site does not try (as of 3 November 2026). ### Where is Alcon in its business cycle? Alcon Inc.'s FY25 operating margin was 12.2%, against a 5-year range of 9.9% to 13.8%: the middle of its own range, neither a peak nor a low. The latest quarter was 14.6%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Alcon story? Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Alcon a stock worth studying right now? What the numbers show: Alcon Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). This is research, not advice. We’re not SEBI-registered.